Lacosamid Hameln (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilising hyper‑excitable membranes and reducing the ability of neurons to fire repetitively. This mechanism diminishes the spread of epileptic activity and helps control seizures.

The specific dose of Lacosamid Hameln is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Lacosamide is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used when the potential benefit justifies the potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide offers a distinct mechanism by enhancing slow inactivation rather than fast inactivation, which may result in a different side‑effect profile. It is often used when patients need additional control without the metabolic interactions seen with some older agents.

Lacosamid Hameln should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discoloured or contains particles.

The product is supplied as an injectable solution for intravenous administration. It can be given as a slow infusion or bolus injection, according to the prescribing clinician’s instructions and the patient’s clinical needs.

Serious risks include cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, and emergence of suicidal thoughts or behaviours. Patients should be monitored closely for any signs of these events, and immediate medical attention is required if they occur.

Lacosamid Hameln is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction abnormalities, severe renal impairment, or those taking interacting medications that could increase toxicity.